The Role of Dendritic and Endothelial Cells in Cardiorenal Syndrome

Grazia Maria Virzi, Jun Zhang, Federico Nalesso, Claudio Ronco, Peter A. McCullough

Keywords
Cardiorenal syndrome · Dendritic cells · Endothelial cells · Endothelial dysfunction · Antigen-presenting cells · Immune dysregulation

Abstract
Backgrounds: Dendritic cells (DCs) are antigen-presenting cells that play a central role in innate and adaptive immune responses; however, the cross talk between cardiac and renal DCs in cardiorenal syndrome (CRS) has not yet been fully elucidated. In this setting, endothelial cells (ECs) also contribute to immune responses. Summary: DC and EC activation and dysfunction have a central role in the pathogenesis of CRS. Regarding immune responses in CRS, it is unknown whether ECs may serve as antigen-presenting cells or act synergistically with DCs to actively participate in innate and adaptive immune responses. This review first focuses on the burden of concomitant heart and renal DCs in the context of CRS; it examines what is known of DCs in animal models, and proposes a central role for DCs in all types of CRS. Second, this review briefly describes the role of ECs in the context of CRS. Key Messages: Understanding the role of DCs and ECs in immune response could lead to the development of novel therapies for the prevention and treatment of CRS.

© 2018 S. Karger AG, Basel
**Introduction**

Dendritic cells (DCs) are antigen-presenting cells that play a central role in innate and adaptive immunology. The definition of DCs is evolving, and it is now clear that different subsets of these cells have unique roles and functions. In human studies, DCs are involved in immune responses and in a vast array of heart and kidney diseases. Many animal models were used to study DCs, and there is an increasing body of evidence on the role of DCs in combined cardiac and renal disease [1–4]. These animal models may have clinical relevance and may be useful to investigate the role of DCs in cardiorenal syndrome (CRS) in humans. Furthermore, cardiac and renal DCs may be involved in the organ cross talk between heart and kidney diseases. In this context, DCs have been postulated as potential mediators involved in the pathogenesis of CRS.

The critical, dynamic, and bidirectional connections between both acute and chronic cardiac dysfunction and acute and chronic kidney disease are well recognized and classified as CRS. CRS classification system has 5 subtypes whose etymology reflects the primary and secondary pathology, the time frame, and the simultaneous cardiac and renal codysfunction secondary to systemic disease [5, 6]. Type 1 CRS represents acute heart failure leading to acute kidney injury (AKI); type 2 CRS represents chronic heart failure leading to kidney failure; type 3 CRS represents AKI leading to acute heart failure; type 4 CRS represents chronic kidney disease leading to heart failure; and type 5 CRS represents systemic disease leading to heart and kidney failure [5–7].

An immune-mediated damage has been postulated as a potential mechanism involved in the pathogenesis of CRS [7]. Alterations in the immune response might include cytokine release and changes in immune cell functions, including apoptosis [8]. Although DCs are potent regulators of immunity, their role in CRS is only partially understood. In this context, there is a pressing and necessary need to translate the findings regarding DCs in animal studies to the human model [7].

In addition, endothelial dysregulation has been increasingly recognized as a contributor to the cross talk between cardiac and renal dysfunction [9–13]. Therefore, endothelial dysfunction has emerged as a critical process in CRS [14]. Recently, endothelial dysregulation has been reported to be associated with type 2 CRS, type 1 diabetes mellitus, and chronic CRS [15–17].

This review will primarily focus on the burden of concomitant heart and renal DCs in the context of CRS; it will examine what is known about DCs in animal models and propose a central role for DCs in all types of CRS. Secondary, this review will briefly describe the role of endothelial cells (ECs) in the context of CRS.

**Overview of DCs in Animal Models for Heart and Kidney Diseases**

In 1981, Hart and Fabre conducted a pilot study about DCs in solid organs; in particular, they investigated DCs in the heart and kidney [18]. Specifically, they established the presence of DCs in the heart and in the kidney and characterized them [18]. Three years later, in a rat model, cardiac DCs were found in the connective tissue between myocytes; in addition, renal DCs were distributed in tubules and glomeruli [19]. In 1986, donor major histocompatibility complex (MHC) class II expression was exclusively confined to DCs in a rat model of acute cardiac allograft rejection [20]. Similarly, in 1993, an increased number of OX6 (MHC class II)+ DCs in the infarcted and border zone, was reported in a rat model of acute myocardial infarction (AMI) [21]. In 2008, Naito et al. [22] studied the different effects of granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF) on infiltration of DCs during early left ventricular (LV) remodeling after AMI. They...
induced AMI by ligation of the left coronary artery in male Wistar rat. G-CSF, a GM-CSF inducer, or saline were administrated for 7 days. They observed that the infiltration by DCs was decreased in rats treated by G-CSF and increased in animals treated by GM-CSF inducer. They concluded that G-CSF improves and GM-CSF exacerbates early postinfarction on LV remodeling in association with modulation of DC infiltration and inflammatory response. In this context, suppression of DC-mediated immunity could be a new promising strategy to treat LV remodeling after AMI [22].

Four years later, DCs were shown to be a potent immunoprotective regulator during the postinfarction healing process in transgenic mice [23]. Based on these findings, cardiac DCs may have detrimental and beneficial effects on AMI [23, 24]. The mechanisms of protection of AMI remodeling by DCs may be related to decrease in proinflammatory macrophages (Ly6C<sup>high</sup> monocytes), increase in anti-inflammatory macrophages (Ly6C<sup>low</sup> monocytes), and production of IL-10 for anti-inflammatory activity [24]. In 1993, DCs, acting as immune effector cells, were observed in a hypertensive rat (SHR) model of Adriamycin-induced cardiotoxicity [25, 26]; subsequently in 2015, renal CD11c<sup>+</sup>/F4/80<sup>+</sup> DCs displayed the phenotypic and functional properties of macrophages in transgenic mice with Adriamycin-induced nephropathy [27]. These data suggest that DCs possess functional plasticity directed by different local environment and stimuli; moreover, DCs have an important role as immune-regulators during steady state as well as serve as a bridge between innate ad adaptive cells in tissue damage and repair.

Additionally, in a rat model with increasing circulating and local angiotensin II (Ang II) levels, Ang II induced renal damage leading to end-organ failure in heart and kidney. Renal DCs expressed MHC class II and CD86 (markers of DC maturation). CD4<sup>+</sup> and CD8<sup>+</sup> T cells were infiltrated in the kidney. These findings suggest that Ang II-induced renal damage is involved in innate and adaptive immune response [28]. In 1994, Kaissling and Le Hir [29] studied the characterization and distribution of interstitial cells in the renal cortex of untreated rats. They showed that in healthy kidneys, renal DCs were present in the inner stripe, in the cortex, and in the outer stripe of the medulla. In the same year, Austyn et al. [30] isolated and cultured DCs from heart and kidney in a mouse model; they showed that these nonlymphoid DCs in situ were relatively immature. The distinction between immature and mature DCs is partly based on changes occurring on the phenotypic and functional levels. Phenotypic maturation is attained when DCs upregulate surface maturation ligands such as CD80, CD83, and CD86 along with the MHC class II molecule [20]. Immature DCs are specialized for antigen capture by endocytosis and macropinocytosis, whereas maturing DCs lose these capacities and acquire stimulatory properties for the activation of naïve T cells and for the development of effector T cells [31, 32].

In 2000, Steptoe et al. [33] performed a comparative analysis of DCs in terms of density and total number in transplanted organs in normal C57BL/6 mice using immunohistochemistry (CD45 and MHC class II staining). They revealed that DC density is greater in the heart than in the kidney or in the pancreas in normal mice. Based on this evidence, remarkable advances have been made regarding the role of renal DCs in rodent models of kidney diseases [34]. Notably, renal DCs were shown to ameliorate cisplatin-induced AKI via endogenous production of IL-10, an immunosuppressive cytokine [35, 36]. The protective role of cardiac DCs for AMI remodeling and renal DCs for cisplatin-induced nephropathy may be important for the modulation of innate or adaptive immunity in cardiovascular and renal diseases. In light of the above hypotheses, DCs may provide a potential novel therapy for CRS in humans [24, 37]. In fact, animal studies have shown that cardiac DCs and renal DCs play a critical role in a variety of cardiac and renal diseases. Although mouse and human DCs differ in some aspects (i.e., some surface markers and cytokine production patterns), basic similarities exist between these species-specific cells [38]. Despite species differences between animals and humans, advances in in vivo or in vitro studies may facilitate patient research regarding CRS.
Rationale for the Role of DCs in Type 2 and Type 4 CRS

It is difficult to extract specific mechanisms for type 2 and type 4 CRS based on human studies, which are mainly observational. Therefore, animal studies may provide important insights into the pathogenesis of CRS by mimicking human phenotypes. Many animal studies on cardiac and renal dysfunction have been performed and described in the literature. Information obtained from these animal studies provides insights into the pathogenesis of CRS.

DC-EC Interaction

Several review and research articles about DC-EC interaction have been published [2, 28, 39–41]. The interaction between DCs and ECs has been exemplified by a primarily nonimmune double-transgenic rat model, in which hypertension led to cardiac and renal failure induced by Ang II [28]. Muller et al. [28] performed in vivo and in vitro study to investigate the role of Ang II in DC maturation. In the kidney, the tubulointerstitium was infiltrated by OX62+ DCs and OX6+ MHCII DCs. Importantly, renal DCs expressed MHC II and CD86 markers, indicating DC maturation. The endothelium was markedly characterized by intercellular adhesion molecule-1 (ICAM-1). Additionally, renal reactive oxygen species were present, and renal nuclear factor kappa B (NF-κB) was activated [28]. They concluded that Ang II induces dendritic migration, and in vivo TNF-α is involved in DC infiltration and maturation. Furthermore, they suggested that immunosuppression prevents DC maturation and T cell infiltration in a nonimmune model of Ang II-induced renal damage [28]. The role of ICAM-1, transcription factor NF-κB, and TNF-α observed in this study was consistent with the concept of EC activation: activated ECs may express endothelial-leukocyte adhesion molecules, such as E-selectin, and P-selectin. In this context, Robert et al. [40] studied the mechanism by which DCs in blood interact with endothelium. In particular, they used an in vivo model of noninfiltrated murine dermal endothelium. In this model, they observed that E- and P-selectin are present in the dermal endothelium and are involved in the interaction between endothelium and blood DCs. Furthermore, Weis et al. [41] investigated the role of endothelial activation and dysregulation of the nitric oxide pathway in DC adhesion and migration. They reported that the adhesion and migration of DCs are increased by stimuli accelerating angiogenesis. In contrast, increased endothelial nitric oxide synthase activity prevents DC adhesion. Activated DCs are involved in the cross talk between DCs and ECs in angiogenesis through the transdifferentiation into ECs [42].

In DCs, low bioavailability of nitric oxide associated with endothelial activation, dysfunction, and apoptosis enhances the capacity of adhesion and migration through vascular ECs [41]. Activated DCs give rise to DC-EC cross talk in angiogenesis. Furthermore, Zhu et al. [43] reported that homocysteine induces endothelial activation: vascular oxidative stress increases DC adhesion and transmigration induced by homocysteine.

Interaction of Cardiac DCs and Renal DCs

It is known that Adriamycin (doxorubicin) induces both cardiomyopathy and nephropathy in an SHR model [25–27]. In this condition, this animal model resembles type 2 and type 4 CRS. Immunohistochemical studies revealed that Adriamycin significantly increases the number of OX6 (MHCII)+ DCs, ED2+ macrophages, CD4+ T helper cells, and CD8+ T cytotoxic/suppressor cells in the heart [25, 26]. Recently, BALB/c mice showed that renal F4/80+ CD11c+ DCs are present in the cortex in Adriamycin-induced nephropathy [27]. These two animal models showed the complementary relationship between cardiac DCs and renal DCs. This line of evidence suggests the interaction between DCs and dysfunction of the heart and kidney is in type 2 or type 4 CRS.
**Cross Talk between Toll-Like Receptors and DCs**

Toll-like receptors (TLRs), important molecules of the innate immune system, control DC maturation by the upregulation of MHC and costimulatory molecules. TLRs link innate and adaptive immunity and secrete cytokines (IL-1β, IL-6, and TNF-α) and chemokines (keratinocyte chemoattractant-1 and monocyte chemoattractant protein [MCP]-1) [44]. In addition, TLRs contribute to myocardial inflammation, myocardial dysfunction, ischemia myocardial injury, AMI, cardiac failure, and hypertension [45–47]. Bomfim et al. [48] reported that TLR4 contributes to blood pressure regulation and vascular contraction in SHR. In fact, cardiac TLR4 expression is augmented in old SHR (15 weeks or older), but not in young SHR or in normotensive Wistar-Kyoto rat. Similarly, TLR4 protein expression in mesenteric resistance arteries is higher in old SHR than in Wistar-Kyoto rats or in young SHR (5-week-old) rats [49].
Bomfim et al. [48, 49] suggested that TLR4 activation contributes to increased blood pressure and vascular contractility; in addition, TLR4 inhibition reduces vascular inflammation in SHR. TLR4 signaling leads to the activation of NF-kB and transcription of the gene involved in inflammatory responses via production of renal reactive oxygen species and expression of IL-6 cytokine in SHR [49]. Production of renal reactive oxygen species, activation of NF-kB, and cytokine release all together have a fundamental role in renal damage [49]. Additionally, TLR4 plays a key role in hypertension-associated remodeling and end-organ damage via pro-inflammatory cytokines (IL-1β and TNF-α) in SHR [50]. TLR4 signaling in the hypothalamic paraventricular nucleus of the brain might be one of the main factors for hypertension development and cardiac remodeling in SHR [51].

TLRs have been implicated in rat kidney diseases. High expression of TLR4 in the glomerular basement membrane, proximal convoluted tubules, and renal interstitial area in Sprague-Dawley rats suggests that TLR4 may activate the immune-inflammatory reaction in diabetic nephropathy [52]. Furthermore, TLR is stimulated by pathogen-associated molecular patterns and by endogenous TLR ligands provided by injured cells. In particular, Lim et al. [53] studied the influence of cyclosporine A (CsA)-induced renal injury on TLR expression. They concluded that CsA-induced renal injury stimulates components of innate immunity, suggesting a close association between CsA-induced renal injury and activation of innate immunity, via TLR-signaling pathway (i.e., increased myeloid differentiation primary-response protein 88 [MyD88], NF-κB, and activator protein-1). In this context, Lv et al. [54] demonstrated the overreactions of LR4-MyD88-NF-κB-dependent innate immunity under high glucose condition, suggesting that TLR4 activates the immune-inflammatory reaction in diabetic nephropathy.

Based on this information extracted from animal models, we propose that cardiac dendritic and renal DCs play a mutual role in type 2 and type 4 CRS (Fig. 1).

**DCs and Ischemia/Perfusion Injury: Potential Link with Type 1 or Type 3 CRS**

Many animal studies on acute cardiac or acute renal dysfunction have been studied and reported in the literature. However, the authors either did not address the function of the other organ of interest or the models they used did not mimic the exact characteristics of clinical type 1 and type 3 CRS. In fact, the heterogeneous character of heart and renal dysfunction in humans limits the possibilities of complete reproduction of these syndromes in animal models. Table 1 presents some animal models with separate ischemia/reperfusion (I/R) injury in the heart or kidney [21, 22, 55–59] that may be used to clarify the emerging role of DCs in type 1 or 3 CRS in humans. However, in these animal studies, there is no direct evidence demonstrating the role of DCs in the bidirectional interconnection between cardiac and renal I/R injury (i.e., from one organ I/R leading to another organ I/R injury), characterizing types 1 and 3 CRS. In spite of this fact, DCs are likely involved in types 1 and 3 CRS. In rat models with acute myocardial ischemic injury without perfusion injury [21, 22] and in rat models with renal I/R injury [55], TLR2 and TLR4 activation, inflammatory cytokine release (IFN-γ), immunosuppressive cytokine release (such as IL-10), and a cascade of DCs and T cell activation were all concomitantly observed. All these data confirm that I/R injury rapidly activates the innate immune response. Furthermore, Dong et al. [60] demonstrated that after I/R injury, renal DCs produce the proinflammatory cytokines/chemokines TNF-α, IL-6, MCP-1, and regulated on activation, normal T cell expressed and secreted (RANTES). Furthermore, the depletion of DCs prior to I/R injury significantly reduced the kidney levels of TNF-α produced after the injury. In contrast, recent work showed the deleterious action of DCs during kidney injury induced by hypertensive stimuli [61, 62]. These findings suggest that
DCs participate in the activation and initiation of immune response and are a key link between innate and adaptive immune responses for myocardial and renal I/R injury. Unfortunately, there are no specific studies about DC depletion in CRS and in heart-kidney cross talk.

**The Role of DCs in Type 5 CRS**

In a mouse model of sepsis multiple-organ dysfunction syndrome (MODS), in the early stage of injury, splenic DCs were mainly activated and increased, and splenic DCs matured to activate lymphocytes to generate the immune response: the immune activation of active DCs was predominant at this stage. At the same time, negative costimulatory molecules were highly expressed, and they have a negative regulatory effect and inhibit the overexpression of immune activity. In the later stage, the DC immune activation function decreased. In addition, the programmed cell death receptor (PD-1) and its ligand (PD-L1) expressions continuously increased, indicating that early active DCs had converted into tolerant DCs. In the MODS stage, the immune tolerance caused by the DCs’ highly negative costimulatory molecules was predominant. The results of this study preliminarily suggest that DCs can regulate T cell function by different costimulatory molecules (i.e., PD-1/PD-L1 pathway) [63].

Lipopolysaccharide (LPS) downregulates the expression of surface markers (CD11c and CD11b) on the splenic DC subset. These changes in DC markers are likely to represent an...
altered function of DCs in the setting of inflammatory conditions [64]. In a mice model, the loss of immature DCs and the inability of mature splenic DCs to produce Th1 cytokines (i.e., IL-12) result in an immunosuppressive effect [65]. Additionally, in LPS-induced sepsis, endogenous glucocorticoids (immunosuppressive hormones) protect mice from LPS-induced septic shock by suppressing DC production of IL-12 (a cytokine required for IFN-γ production and lethality in LPS-induced septic shock) [65]. Kobayashi et al. [66] reported that B and T lymphocyte attenuator (CD272) inhibits LPS-induced endotoxic shock by suppressing TLR4 signaling and proinflammatory cytokine production in DCs. These findings suggest that the cellular and molecular mechanisms responsible for endotoxin tolerance are multifactorial and likely involve negative feedback at multiple levels in multiple cell types.

The Potential of Human Study on DCs

On the basis of animal studies on DCs, further research is warranted to determine the emerging role of DCs in human CRS, to prove both detrimental and beneficial effects of DCs on humans, and to explore their potential as therapeutic targets. Therefore, a better understanding of the interplay between the immune system and cardiac/renal dysfunction will be critical for developing novel therapeutic treatments and innovative approaches for monitoring the progression of CRS. There is growing evidence to suggest that the phenotypes and functions of DCs in animals and humans are similar in some aspects. For example, loss of DCs has been observed in septic patients and in experimental sepsis models [65]. The B and T lymphocyte attenuator directly inhibits LPS response in DCs; thus, agonistic agents for the B and T lymphocyte attenuator might have therapeutic potential for LPS-induced endotoxic shock [66]. In AMI of patients, DCs, macrophages, and T cells initiate an immune response against cardiac antigens, leading to further myocardial damage [67]. Human DCs are characterized by HLA-DR (MHC classII) and spindle-shaped morphology with long, slender, dendritic processes, which are in close contact with myocytes. Yokoyama et al. [1] reported that, in the human heart, cardiac DCs may be recruited in the acute phase of myocarditis, and seem to play an important role in the subsequent immunoreponse. Furthermore, in acute myocarditis, DCs present altered cardiac myosin molecules released from injured cardiomyocytes to helper T lymphocytes. Interestingly, a protective role of DCs was detected in postmyocardial infarction inflammation [68]. Therefore, it should be reminded that the immune system of mice and humans differs in considerable aspects, and more studies are required in patients because many pathogenic factors, tumors, microbes, or allergens, a stimulus for autoimmune or autoinflammatory disease, cannot easily or totally be modeled in mice.

Can ECs Function as Antigen-Presenting Cells in CRS?

Endothelial cells (ECs) are located at the interface of blood and tissues, and display regulatory activities toward coagulation, inflammation, and vascular homeostasis. By expressing MHC class I and II antigens, ECs also contribute to immune responses [69]. Like DC activation and maturation, EC activation and dysfunction play a pivotal role in the pathogenesis of CRS [14]. Regarding immune responses in CRS, it is unknown whether ECs may serve as antigen-presenting cells or act synergistically with DCs to actively participate in innate and adaptive immune responses. In this context, little is known about CRS in humans. However, there is growing evidence to suggest that cultured human ECs act as nonprofessional antigen-presenting cells that are likely capable of presenting antigens to T cells [70–72]. ECs are so-called nonprofessional antigen-presenting cells because they appear to be less potent
stimulators of T cells than conventional professional antigen-presenting cells (e.g., DCs, monocytes, macrophages, and B cells). Therefore, the number of T cells activated by ECs is far fewer than those activated by professional antigen-presenting cells [5]. In the setting of ECs as antigen-presenting cells, attention has been focused on cytokine-induced endothelial activation, cytokine-increased MHC class I or II molecules in the endothelium, and cytokine-induced cell adhesion molecules (e.g., ICAM-1, ICAM-2, VCAM-1, E-selectin, p-selectin) in the endothelium. It has been shown that cytokines such as interferon family (IFN-α, IFN-β, and IFN-γ), TNF family (TNF-α, TNF-β), IL-1, and IL-2 act to increase MHC class I or II antigen expression in the endothelium [71]. In particular, TNF can enhance IFN-γ-induced MHC class I and II antigen expression on human ECs [70], which can directly activate resting CD8 T cells; further, IFN-γ-pretreated ECs can activate CD4 T cells [71]. These actions enhance the ability of ECs to participate in immune reactions [71].

In the setting of an immune rejection reaction associated with transplantation, it has been suggested that human ECs as antigen-presenting cells participate in delayed hypersensitivity [71]. In this context, there is a difference in MHC class II antigens between rodent models of allograft rejection and patient transplant rejection [71]. Both rodent and human ECs express MHC I antigens. In rodents, the unique source of donor MHC class II is bone marrow-derived passenger leukocytes (DCs and macrophages). In contrast, in humans, endothelium located in the capillaries, arterioles, coronary arteries, and venules (but not in the aorta, pulmonary artery, and saphenous vein) contains MHC class II (HLA-DR and DP) antigens [71]. These differences may explain why it is easier to suppress transplant rejection in rodents than in humans [71]. The phenotypic properties of human ECs, their response to cytokines, and their ability to stimulate resting T cells allow human ECs to act as antigen-presenting cells in allograft rejection following cardiac and renal transplantation [71].

Recent evidence suggests that ECs actively participate in innate and adaptive immune responses [73]. Furthermore, ECs are a passive target of the host immune response but also an active player in lymphocyte activation [74]. Recent data reported that IFN-γ stimulates endothelial cells that become capable of inducing Foxp3⁺ regular T cells, crucial mediators of immune tolerance [74]. Additionally, ECs express a set of MHC class I-like or structural-related molecules, such as HLA-E, MHC class I-related chain A, and the endothelial protein C receptor; these new molecules provide multiple and unique function to endothelial cells [69]. These facts along with the new concept of endothelial plasticity suggest that ECs are dynamic cells that respond to extracellular environmental changes and play a meaningful role in immune system function [73].

The above-cited information about human ECs allows to hypothesize that ECs are likely to be nonprofessional antigen-presenting cells in human CRS. Our observations, in addition to data on endothelial dysfunction [14] and heart-kidney cross talk in the setting of immune system cells [7], suggest that professional antigen-presenting cells (DCs, monocytes, macrophages, B cells), nonprofessional antigen-presenting cells (ECs), and other immune cells (lymphocytes, neutrophils, etc.) play an important role in innate and adaptive immune responses to CRS. In particular, experimental data demonstrated that a defective regulation of monocyte apoptosis and an immune-mediated mechanism play a fundamental role in the pathophysiology of type 1 CRS [75].

**Conclusion**

Our knowledge of DC biology is likely to be markedly extended to dissect the pathogenic processes of CRS for prevention and treatment. Especially, progress has been made in DC biology of animal models. Evidence from animal models suggests that DCs play a role in CRS
types 2 and 4, and they may also be involved in types 1, 3, and 5. Unfortunately, very little information is available with regard to the precise mechanism whereby DCs contribute to CRS. Further study is need to elucidate the role of DCs in CRS; particularly, the molecular mechanism involved in the tissue dysfunction observed in these syndromes. In addition, new animal models, which may include both heart and kidney disease and involve cardiac and renal DCs, the interaction of DCs and ECs, and cross talk between DCs and TLR4 or TLR2 are necessary to better understand CRS. Further investigations, further studies, further in vitro experiments, and specific animal models are therefore necessary to better understand this pathophysiological process and the therapeutic and prognostic implications for DCs in all types of CRS.

All these approaches help us to understand the exact role of DCs in CRS and the exact molecular and submolecular mechanisms involved. These approaches are very important and fundamental to explore how DCs contribute to tissue dysfunction in heart and kidney in CRS. Finally, there is still a lack of translational investigations in human studies. Resolving this issue is crucial because translation can prove both the detrimental and beneficial effects of DCs on humans and discover the underlying pathogenetic mechanisms. In addition, answering the many open questions with regard to the role of DCs in immune tolerance could lead to the development of novel therapies for the prevention and treatment of CRS.

Acknowledgement

The authors thank Alan D. Knapton (US FDA) for the technical assistance in figure preparation. The authors also thank Adam Stephens (the Publications Office, Baylor Scoot & White Health) for expert assistance in editing the manuscript.

Statement of Ethics

This work did not involve human subjects or animals and was exempt from review by Baylor Institutional Review Board.

Disclosure Statement

There are no conflicts of interest to disclose.

Funding Sources

Funding for this work was obtained from Baylor Heart and Vascular Institute.

References


